Neuralink gets US FDA approval to implant its brain chip in a second person; source: FDA signed off on proposed fixes like embedding wires deeper into the brain
Elon Musk-backed startup has proposed solutions for thread pullout problem experienced by first participant, Noland Arbaugh
Context & Ripple Effects
Neuralink’s second-person authorization follows its initial FDA clearance for a first-in-human study and subsequent enrollment of paralysis patients. The program is still operating as a small clinical trial rather than a commercial rollout.
The decision comes after Neuralink disclosed that thread pullout in Noland Arbaugh’s implant had reduced data collection; the FDA’s acceptance of proposed changes addresses that earlier implant-performance problem sufficiently to continue the study.
First-order effects
- Neuralink can proceed with implanting a second trial participant under an FDA-approved remediation plan, including deeper wire placement.
- The company’s immediate clinical focus shifts from diagnosing the first participant’s thread issue to testing whether the revised procedure preserves electrode performance and data collection.
Second-order effects
- The second implant creates a direct comparison point for Neuralink’s revised approach, making subsequent trial progress more dependent on repeatable performance than on a single participant outcome.
- Other brain-computer-interface developers and clinical partners face a clearer signal that device-design and surgical issues can be handled through iterative FDA-reviewed trial changes, while remaining subject to close safety scrutiny.
Third-order effects
- If revised implants perform reliably across participants, invasive brain-computer interfaces may increasingly develop through an iterative clinical-engineering loop: early failures, disclosed fixes, and regulator-approved retesting.
- The durable constraint remains evidence quality: small trials can establish feasibility, but broader adoption will depend on whether safety and device reliability hold beyond isolated cases.
The trend: Brain-computer interface development is moving from initial human implantation toward regulator-supervised iteration on the reliability problems exposed by real-world use.